Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, and Innovation Zed, a pioneering developer of connected add-on devices for drug delivery devices, today announced a strategic partnership to develop and deploy digital companion apps with the adaptive DOSE platform hardware add-on technology for injectable therapies. This collaboration aims to revolutionize the management of injectable medications by providing comprehensive connectivity and data capture solutions for dosing, storage, and injection techniques.

Addressing the Challenges of Injectable Therapies

Injectable therapies are essential for managing many chronic conditions, yet they pose significant challenges. Complex dosing regimens, fear of injections, and variability in injection technique can hinder adherence and compromise safety. Additionally, improper storage can impact medication efficacy, while limited data capture makes it difficult to monitor patient progress effectively. This collaboration aims to address these challenges by providing a comprehensive digital solution that supports patients and healthcare providers in optimizing injectable therapies.

Glooko and Innovation Zed’s Innovative Technology

This innovative digital companion system, seamlessly integrating hardware and software, will be designed to integrate with the Glooko platform, currently used by over 8,200 diabetes clinics worldwide. This integration will enable the capture and analysis of critical information related to injectable therapies from Innovation Zed’s DOSE platform technology, offering enhanced support for healthcare providers and patients alike.

Key Benefits of the Digital Companion Apps:

• Improved Adherence: Accurate recording and monitoring of dosing schedules to support adherence and optimize therapy outcomes.
• Enhanced Safety: Guidance on proper storage conditions to maintain medication efficacy and educational resources on correct injection techniques.
• Increased Patient Confidence: Support and feedback on injection techniques to improve patient confidence and safety.
• Streamlined Data Management: Real-time data capture and connectivity for a wide range of injectable medications, providing valuable insights for healthcare professionals.

Expanding Access and Gathering Real-World Data

By leveraging the extensive reach of the Glooko platform, this partnership offers industry partners a valuable launchpad into key markets, enhancing the accessibility and effectiveness of injectable therapies globally. This constitutes a unique opportunity for the pharmaceutical industry to gather valuable real-world data in real-time, leading to a deeper understanding of patient behavior.

“We are excited to partner with Innovation Zed to bring this cutting-edge digital companion system to market,” said Mike Alvarez, Chief Executive Officer of Glooko. “This collaboration will enable us to provide comprehensive support for patients and their healthcare providers, ultimately enhancing the treatment experience and improving outcomes. This partnership, combined with our ongoing platform development, reflects Glooko’s continued focus on increasing the benefits delivered to patients and clinics.”

“Our partnership with Glooko represents a significant step forward in the integration of our smart drug delivery solutions with a leading digital health platform,” said Dr. Dean Minnock, Chief Executive Officer of Innovation Zed. “Together, we can offer unparalleled support to patients and healthcare providers, improving the management of injectable therapies worldwide.”

About Glooko

Glooko improves health outcomes of people with chronic conditions through personalized, intelligent, connected care and life sciences platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko solutions are globally deployed in more than 30 countries, 10,000+ clinical locations* and partner to connect with over 200 devices. With more than 4.4 million people worldwide who have used Glooko platforms, Glooko boasts the largest installed base of patients living with diabetes. For more information, please visit glooko.com.

About Innovation Zed

Innovation Zed is a leading provider of connected health solutions, specializing in developing innovative medical devices to support drug adherence and diabetes management. With a focus on leveraging technology to enhance patient outcomes, Innovation Zed continues to pioneer new methods for personalized condition management and improved drug adherence. Visit www.innovationzed.com to learn more.

Contact:

Glooko Media Relations
Email: [email protected]
Phone: +1 (800) 206-6601

Julia Fuller
[email protected]
(858) 692-2001

Innovation Zed Media Relations
Email: [email protected]
Phone: +353 (1) 437-0331

*This count indicates the number of health clinics that have registered and uploaded health data over the 14 year period with one of the Glooko solutions, which are the Glooko® System, Glooko XT®, and diasend® System.

MKTG-0338

Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, today announced that its Glooko XT solution has been approved for reimbursement by the Haute Autorité de Santé (HAS) and the Commission Nationale d’Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) in France. This decision, published in the French Journal Officiel (JO) on December 26, 2024^{1, 2}, allows healthcare providers to receive reimbursement for remote monitoring of gestational diabetes (GDM) in patients not treated with insulin.

This expands upon the existing reimbursement for Glooko XT for remote monitoring of people with insulin-treated diabetes, making it one of only two solutions in France with this GDM indication and further demonstrating the value of this technology in diabetes management.

GDM has a significant impact on maternal and fetal health in France:

• Prevalence: GDM affects an estimated 8.8% of pregnancies in France.³ 

• Health Risks: GDM increases risks of preeclampsia, cesarean delivery, and type 2 diabetes in mothers. For newborns, it can lead to macrosomia, preterm birth, and respiratory distress.⁴ 

The HAS approval is based on the recognition that Glooko XT provides a valuable complementary monitoring option for conventional medical follow-up of GDM. The specific indications for reimbursement include:

• Non insulin treated pregnant women diagnosed with GDM through a positive oral glucose tolerance test (OGTT) performed between the 24th and 28th week of amenorrhea, or with a fasting blood glucose level greater than or equal to 0.92g/L during the first trimester of pregnancy in the presence of at least one risk factor.

Expanding reimbursement for GDM ensures equitable access to this vital technology, supporting healthier pregnancies and improved outcomes for mothers and babies.

“This is a significant milestone for Glooko and for the management of gestational diabetes in France. We are proud that the French health authorities recognize the benefits of Glooko XT for the health of patients, and we are committed to providing a reliable and secure platform for the management of gestational diabetes in France,” said Mike Alvarez, Chief Executive Officer of Glooko. “By enabling remote monitoring, we can empower healthcare providers to deliver more personalized and timely care to pregnant women with GDM, potentially contributing to better outcomes for mothers and babies. This approval also reinforces Glooko’s commitment to expanding access to innovative digital health solutions globally.”

Glooko XT: Tailored for the French Healthcare Landscape

Glooko XT simplifies remote patient monitoring by providing healthcare professionals with a comprehensive view of their patients’ diabetes data, including blood glucose readings, insulin doses, carbohydrate intake, and activity levels. The platform also allows for secure messaging and communication between patients and providers, facilitating timely interventions and support.
Glooko XT in France complies specifically with French regulations on health data management. These regulations, some of the most stringent in the world, prioritize patient privacy and data security. Glooko XT has been meticulously designed to meet these requirements, including features that ensure data sovereignty, robust security measures, and full compliance with the General Data Protection Regulation (GDPR) and guidelines established by l’Agence du Numérique en santé, as outlined in the relevant legal texts governing health data in France. This commitment to data privacy allows Glooko to provide a trusted and secure platform for both patients and healthcare professionals in France.

About Glooko

Glooko improves health outcomes of people with chronic conditions through personalized, intelligent, connected  care and life sciences platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials.  Glooko solutions are globally deployed in more than 30 countries, 10,000+ clinical locations* and partner to connect with over 200 devices. With more than 4.4 million people worldwide who have used Glooko platforms, Glooko boasts the largest installed base of patients living with diabetes. Glooko XT and Glooko are Class IIa medical devices certified under the EU Medical Device Regulation (MDR). For more information, please visit glooko.com or glookoxt.com.

Media Contacts:    
[email protected]  

1. Arrêté du 26 décembre 2024 portant inscription d’activités de télésurveillance médicale sur la liste prévue à l’article L. 162-52 du code de la sécurité sociale https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000050872057
2. Arrêté du 26 décembre 2024 fixant le montant d’un forfait technique applicable à une activité de télésurveillance inscrite sur la liste des activités de télésurveillance médicale prévue à l’article L. 162-52 du code de la sécurité sociale https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000050872088
3. International Diabetes Federation, 2021
4. Chiefari et al., 2017

*This count indicates the number of health clinics that have registered and uploaded health data over the 14 year period with one of the Glooko solutions, which are the Glooko® System, Glooko XT®, and diasend® System.

MKTG-0337

New integration delivers personalised insulin dosing advice, improving care for people with diabetes and enhancing healthcare provider insights.

COPENHAGEN, Denmark and Palo Alto, CA, USA, January 8, 2025

Glooko, Inc. and Hedia, today announced the launch of their interoperable solution, which combines connected care, remote patient monitoring, and digital therapeutic technologies to enhance access for people with Type 1 and Type 2 diabetes requiring advanced bolus insulin dosing support in their daily management. This launch is currently available in the United Kingdom and will be followed by rollouts in other European countries.

A bolus is an extra amount of insulin taken to cover an expected rise in blood glucose, often related to a meal or snack.^[1] Generally, to correct a high blood sugar, one unit of insulin is needed to drop the blood glucose by 50 mg/dl, however, this can vary across individuals.^[2] For people with diabetes who do not have an insulin pump, calculating the appropriate bolus dose can present a challenge for them and their physicians.

With the Glooko platform, patients can share their diabetes data with their healthcare providers (HCPs), including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure, and weight. The integration of Hedia Diabetes Assistant with Glooko’s platform provides patients with seamless, personalised support in calculating insulin doses, simplifying their diabetes management and supporting more consistent blood glucose levels. Healthcare providers benefit from enhanced visibility into their patients’ health data through convenient access to blood glucose readings, insulin doses, carbohydrate intake, physical activity, and more. This streamlined approach to managing multiple daily injections (MDI) helps improve both patient outcomes and provider efficiency in remote and in-person care settings.

“We are very pleased to bring this algorithm-driven, personalised innovation to diabetes patients and their healthcare teams through our partnership with Hedia.” stated Mike Alvarez, Chief Executive Officer of Glooko. “With extensive clinical data supporting Hedia’s efficacy, this solution provides an alternative for those unable to access insulin pumps, ensuring more effective management of MDI therapy. This partnership reflects Glooko’s commitment to advancing digital health tools that optimise diabetes care and help stabilise blood glucose levels through personalised, connected care.”

“We are thrilled to be partnering with Glooko, a digital health company with an extensive clinical network, said Lars Christian Lund, Chief Executive Officer of Hedia. “This joint offering is perfectly aligned with Hedia’s vision to improve the quality of life for people with diabetes and make the best diabetes management tools available. In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance, and we recently got MDR certified in Europe. Hedia’s Class IIb medical device designation ensures that patients and their care teams are getting the best solutions.”

About Hedia
Hedia is a leading digital therapeutics company within diabetes, committed to help people with insulin-dependent diabetes gain control of their condition. Making life with diabetes easier has been the incentive from the beginning of building Hedia Diabetes Assistant. Based on the habits of the individual person with diabetes and personalised input, our diabetes app generates insulin recommendations by taking many aspects of diabetes management into account – such as recording blood glucose readings, keeping track of active insulin, measuring carbs, keeping track of activity and recording blood ketones.

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care and life sciences platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in more than 30 countries and 10,000+ clinical locations*. More than 4.4 million people worldwide have used the Glooko platform. Glooko is a Class IIa medical device certified under the new Medical Device Regulation (MDR). For more information, please visit glooko.com.

Media Contacts:
[email protected]

Julia Fuller
[email protected]
(858) 692-2001

^[1] American Diabetes Association, Common Terms
^[2] UCSF, Diabetes Education Online
* This count indicates the number of health clinics that have registered and uploaded health data over the 14 year period with one of the Glooko solutions, which are the Glooko® System, Glooko XT®, and diasend® System.

MKTG-0336

PALO ALTO, Calif. Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma and medical device partners, today announced that it has secured a $100 million Series F financing. The Company’s Board of Directors also announced the appointment of Mike Alvarez as Chief Executive Officer.

The financing round, led by Georgian, with investments from Health Catalyst Capital, Canaan and other investors and business partners, will support Glooko’s continued growth and product expansion in expert data insights, device integrations, clinical research and chronic condition support for healthcare providers around the world. This funding, coupled with the appointment of Mr. Alvarez as CEO, will allow Glooko to accelerate global product expansion of its cutting-edge digital healthcare platform and life sciences work, which empowers people with diabetes to better manage their condition and strengthen the engagement with and care from their healthcare team.

“On behalf of the Board of Directors, we are delighted to welcome Mike Alvarez as the new leader of Glooko,” said Simon Chong, Co-Founder at Georgian and Chairman of the Board of Directors for Glooko. “Today, more than 537 million adults worldwide are diagnosed with diabetes, and the numbers are projected to grow every year. The need for timely, comprehensive and integrated support for healthcare practitioners is critical. Mike brings significant industry expertise, proven leadership and commercial success across chronic condition management and population health, as well as experience with advanced data management technologies. We believe Mike is the right leader at a key inflection point for Glooko and look forward to working with him.”

Mr. Alvarez brings more than two decades of leadership experience with multinational companies in medical devices and biotechnology. Most recently, Mr. Alvarez served as Chief Executive Officer of Qardio, a leader in remote patient monitoring and technology solutions for chronic disease management. Prior to Qardio, Mr. Alvarez held leadership positions at Medtronic, St. Jude Medical (acquired by Abbott), and Sanofi.

“The healthcare industry is currently navigating significant challenges related to data burden and clinical workflows, particularly for physicians working with patients to manage chronic conditions,” said Mr. Alvarez. “By unifying data from multiple devices onto one standardized platform, we can simplify decision-making and empower providers to translate vast amounts of data into meaningful insights. This enables timely interventions and helps create new clinical care pathways that can enhance patient outcomes. I am thrilled to join Glooko at this pivotal moment in its journey. I look forward to continued commercial acceleration as we leverage real-world data to transform chronic condition management and improve enrollment and management in clinical trials through diverse and inclusive populations.”

About Glooko

Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care and life sciences platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. More than 4.4 million people around the world with diabetes have used the Glooko platform. For more information, please visit our website.

About Georgian

Georgian invests in high-growth B2B software companies and builds software to help those companies scale faster through our AI Lab. We seek to identify and accelerate leading growth-stage software companies in our thesis areas of Applied AI and Trust. Based in Toronto, Georgian’s team brings together investors with machine learning professionals, software entrepreneurs and experienced operators. Founded in 2008, Georgian has US$5.6B AUM as of December 31, 2023.

Contacts

Media Inquiries:
Liz Horgan
Chief Marketing Officer
Glooko
[email protected]

Julia Fuller
Managing Partner
Ford Hutman Media
[email protected]

James Lamberti
Head of Go to Market
Georgian
[email protected]

 Palo Alto, CA, USA – October 25, 2023 – Glooko, Inc., a global leader in chronic condition management, specializing in connected care and remote patient monitoring for diabetes and other related diseases, today announced the appointment of Enrique Conterno to its Board of Directors.

Mr. Conterno is a well-known executive in the pharmaceutical industry with deep expertise in the diabetes field. He joins the board of Glooko having served most recently as the Chief Executive Officer and a member of the Board at FibroGen, Inc. Before FibroGen, Mr. Conterno was Senior Vice President for Eli Lilly and Company, serving as President of Lilly USA from January 2017, and President of Lilly Diabetes from 2009, until his retirement from Lilly in December 2019. Prior to 2009, Mr. Conterno served in various other roles for Eli Lilly and Company, including President, U.S. Operations, Vice President for the U.S. Neuroscience Business Unit, President and General Manager, Mexico, and Executive Marketing Director, Intercontinental Operations and Japan.

Mr. Conterno earned a Bachelor of Science degree in Mechanical Engineering from Case Western Reserve University and a Master of Business Administration from Duke University. He is a member of the Board of Governors of the American Red Cross.

“We are extremely pleased to welcome Enrique to our Board. His deep knowledge of the diabetes space and his leadership of the diabetes enterprise at Lilly will be invaluable to Glooko as we grow our connected care business in diabetes and related chronic conditions as well as our digital life sciences practice,” said Russ Johannesson, CEO of Glooko. “In addition, his broad experience from his operational, marketing and growth leadership roles will help to guide our strategic vision of becoming the go-to platform for chronic care management.”

Mr. Conterno has deep familiarity with the global healthcare ecosystem and has overseen multiple, important major product launches in the diabetes space. His three decades of leadership and proven track record of growing revenues and businesses will further enhance Glooko’s already significant global positioning in the digital life sciences marketplace.

“I am delighted to join the board of Glooko during this pivotal and important time in the company’s history and look forward to working with the team to grow the diabetes franchise as well as penetrate the rapidly growing adjacent areas, including obesity and cardiometabolic disease,” said Mr. Conterno. “Glooko brings innovative digital health solutions to patients, providers, and clinical and pharmaceutical companies around the world. I am excited to leverage my insights to help Glooko to reach its full potential.”

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

###

Media Inquiries:
Kris Lawrence
Vice President, Global Marketing
[email protected]

Verbesserungen bieten eine nahtlose Erfahrung und ebnen den Weg für „Precision Engagement“ im Gesundheitswesen

Palo Alto, Kalifornien, USA – 9. Mai 2023 – Glooko, Inc. kündigte heute die Umgestaltung ihrer preisgekrönten mobilen App für die vernetzte Versorgungsplattform an, die den Benutzern ein optimiertes Erlebnis bieten wird. Das schlanke, moderne Design erleichtert die Navigation durch alle robusten Funktionen in der mobilen Glooko-App für ein besseres Diabetesmanagement. Wenn die App mit dem medizinischen Fachpersonal des Benutzers verbunden ist, enthält die neueste Version der App auch Verbesserungen, die eine Personalisierung der Versorgung durch eine bevorstehende Weiterentwicklung ermöglichen, das sogenannte „Precision Engagement“.

„Als weltweit führender Anbieter von Connected Care ist Glooko Vorreiter bei der Nutzung unserer mobilen App zur Verbesserung des Diabetesmanagements“, so Ed Marshall, Chief Product Officer bei Glooko. „Mit der zunehmend fragmentierten medizinischen Versorgung von heute ist es ein Privileg und eine riesige Chance für Glooko, die Verbindungen zwischen Patienten und ihrem Behandlungsteam zu stärken. Dies ist eine wichtige Investition, mit der Glooko die Benutzererfahrung weiter verbessern will, um sie bequemer, individueller und letztendlich wirkungsvoller zu gestalten.“

Bei der Entwicklung des neuen App-Erlebnisses war die Interaktion mit den Benutzern von entscheidender Bedeutung. Die Umgestaltung der App basiert auf dem Feedback von Glooko-Benutzern, die visuelle Verbesserungen und ein neues einheitliches Design als Teil einer allgemeinen Weiterentwicklung der digitalen Gesundheitsplattform sehen werden.

Zu den Verbesserungen gehören:

• Benutzeroberfläche und Datenvisualisierung -> Das neue Design der mobilen App erleichtert es Benutzern, ihre Daten an einem Ort zu organisieren und mit ihren medizinischen Fachkräften zu teilen, z. B. Glukosetrends, Insulindosen, Nahrungsmittel, Bewegung, Gewicht und Blutdruck. Der Name des Pflegeteams oder der Klinik wird oben auf dem Bildschirm angezeigt und kann angeklickt werden, um Berichte an medizinisches Fachpersonal weiterzuleiten. So können alle aktiven Behandlungsteams an einem Ort angezeigt werden.

• Startbildschirm -> Neue Navigation ermöglicht Benutzern den effizienten Zugriff auf beliebte Funktionen wie die Protokollierung von Lebensmitteln und die Weitergabe von Daten an Behandlungsteams, die in einem Bildlauf (One Scroll) verfügbar sind und die aktuellsten Daten zu ihrer Gesundheit enthalten. Die One-Scroll-Funktion auf der Startseite umfasst außerdem: Profileinstellungen, Name des Betreuungsteams, Ziele, Verlauf, angeschlossene Geräte, Schaltfläche zum Hinzufügen neuer Ereignisse, Diagramme und Grafiken mit Daten von zwei Wochen.

• Onboarding-Prozess -> Für Benutzer, die Glooko noch nicht kennen, ist das Onboarding jetzt einfacher. Der neu gestaltete Onboarding-Prozess leitet neue Benutzer einfach und schrittweise durch den Prozess, sodass sie es in ihrem eigenen Tempo durchführen können. Neue Anwender erhalten einfache Hilfe bei: Auswahl ihres Glukosegerätes, Auswahl ihres Insulingerätes, Vervollständigung ihres Profils.

• Precision Engagement -> Das neue Design wurde mit der Fähigkeit entwickelt, die kommende Funktionalität von Glooko, „Precision Engagement“, aufzunehmen Precision Engagement-Tools nutzen Umwelt-, Verhaltens- und physiologische Daten von medizinischen Geräten, Wearables, Verbrauchergeräten und Smartphones, um die individuellen Vorlieben, Gewohnheiten und die Umgebung einer Person besser zu verstehen. Mit diesen einzigartigen Erkenntnissen erkennt Glooko die richtigen Zeitpunkte und möchte personalisierte Empfehlungen geben, um das Verhalten zu beeinflussen. In naher Zukunft wird Glooko weitere Informationen zu Precision Engagement bekannt geben.

Die Aktualisierungen fallen mit anderen wichtigen Meilensteinen für Glooko zusammen:

• Die mobile App ist weltweit in mehr als 30 Ländern und mehr als 20 Sprachen verfügbar und wächst stetig.

• Glooko ist jetzt weltweit mit über 200 Diabetes- und biometrischen Geräten kompatibel und hat damit die größte Kompatibilität aller vernetzten Behandlungsplattformen.

• Über 8.000 Kliniken weltweit betreuen Patienten mit Glooko.

• Glooko ist die einzige Plattform für vernetzte Versorgung, die mit allen wichtigen smarten Insulin-Pens und pharmazeutischen Herstellern kompatibel ist.

Über Glooko
Glooko verbessert die gesundheitlichen Perspektiven von Menschen mit chronischen Erkrankungen durch eine personalisierte, intelligente und vernetzte Versorgungsplattform. Unsere bewährten Technologien sorgen für bessere Lebensqualität, indem sie die Verbindung zwischen Patienten und Anbietern revolutionieren, die Patientenbindung und Therapietreue über digitale Therapeutika fördern und klinische Studien beschleunigen. Glooko ist weltweit in mehr als 30 Ländern und an über 8.000 klinischen Standorten vertreten.

Glooko.com LinkedIn.com Twitter Instagram Facebook

###

Medienkontakt
Tanya Rodante
Director of Global Communication
[email protected]

Les améliorations apportées à cette application rendent son utilisation plus fluide et posent les bases d’une gestion des soins avec un « engagement de précision »

Palo Alto, Californie, États-Unis, 9 mai 2023 : Glooko, Inc. a annoncé aujourd’hui la refonte de son application mobile primée pour sa plateforme de soins connectés. Elle offrira une expérience plus rationalisée à ses utilisateurs mobiles. Sa conception élégante et moderne permet de naviguer encore plus facilement à travers toutes les fonctionnalités performantes de l’application mobile Glooko pour une meilleure gestion du diabète. Lorsque les utilisateurs sont connectés à leurs professionnels de santé, la dernière version de l’application inclura également des améliorations pour personnaliser leurs soins à l’aide d’une fonction avancée appelée « Engagement de précision ».

Ed Marshall, chef de produit chez Glooko, a déclaré : « En tant que leader mondial dans le domaine des soins connectés, Glooko a optimisé notre application mobile pour améliorer la gestion du diabète. Dans le contexte actuel de prestations de soins de plus en plus fragmentées, c’est un privilège et une énorme opportunité pour Glooko de renforcer les liens entre les patients et leur équipe soignante. Il s’agit d’un investissement important pour Glooko, qui vise à améliorer encore l’expérience utilisateur, en la rendant plus pratique, plus personnalisée et enfin, plus percutante. »

Lors du développement de cette nouvelle version de l’application, l’engagement des utilisateurs était essentiel. La refonte de l’application a tenu compte des commentaires des utilisateurs de Glooko, qui découvriront des améliorations visuelles et une nouvelle conception unifiée dans le cadre d’une évolution globale de la plateforme de santé numérique.

Les améliorations incluent les éléments suivants :

• Interface utilisateur et visualisation des données -> La nouvelle conception de l’application mobile permettra aux utilisateurs d’organiser leurs données en un seul endroit et de les partager avec leurs professionnels de santé. Ces données incluent les tendances glycémiques, les doses d’insuline, l’alimentation, l’exercice, le poids et la tension artérielle. Les utilisateurs verront le nom de leur équipe soignante ou de leur clinique en haut de l’écran. En cliquant dessus, ils pourront partager des rapports avec leur professionnel de santé et voir toutes les équipes soignantes actives dans un seul et même endroit.

• Écran d’accueil -> La nouvelle navigation permettra aux utilisateurs d’accéder efficacement aux fonctionnalités courantes, telles que la saisie des repas et le partage de données avec les équipes soignantes. Elles seront toutes disponibles grâce à un seul défilement et présenteront les données les plus récentes sur leur santé. La fonction de défilement unique de l’écran d’accueil comprendra également : les paramètres de profil, le nom de l’équipe soignante, les objectifs, l’historique, les appareils connectés, un bouton pour ajouter un nouvel événement, ainsi que des graphiques et des diagrammes comportant deux semaines de données.

• Processus d’intégration -> Pour les nouveaux utilisateurs de Glooko, l’expérience d’intégration sera désormais plus simple. Le processus d’intégration repensé guidera et accompagnera les nouveaux utilisateurs de manière simple et « succincte », ce qui leur permettra de découvrir l’application à leur propre rythme. Les nouveaux utilisateurs seront guidés afin de pouvoir plus facilement : sélectionner un lecteur de glycémie, sélectionner un dispositif d’injection d’insuline et compléter leur profil.

• Engagement de précision -> La nouvelle conception a été pensée pour pouvoir spécifiquement accueillir la prochaine fonctionnalité de Glooko : « l’engagement de précision ». Les outils d’engagement de précision exploitent les données environnementales, comportementales et physiologiques des dispositifs médicaux, portables, grand public et des smartphones pour mieux comprendre les préférences, habitudes et environnement uniques d’un individu. Grâce à ces informations uniques, Glooko détecte les bons moments et vise à fournir des recommandations personnalisées pour influencer le comportement des utilisateurs. Glooko fournira bientôt davantage d’informations sur l’engagement de précision.

Ces mises à jour coïncident avec d’autres grandes étapes pour Glooko :

• L’application mobile est disponible dans plus de 30 pays et dans plus de 20 langues, et ce n’est qu’un début.

• Glooko est désormais compatible avec plus de 200 dispositifs biométriques et de surveillance du diabète dans le monde, la plus grande compatibilité de toutes les plateformes de soins connectées.

• Plus de 8 000 cliniques dans le monde sollicitent Glooko pour soigner leurs patients.

• Glooko est la seule plateforme de soins connectée compatible avec tous les principaux stylos à insuline connectés et fabricants pharmaceutiques.

À propos de Glooko
Glooko améliore les résultats de santé des personnes souffrant de maladies chroniques grâce à sa plateforme de soins personnalisée, intelligente et connectée. Nos technologies éprouvées améliorent la vie des patients en révolutionnant le lien entre les patients et les prestataires de soins, en favorisant l’engagement et l’adhésion des patients via des thérapies numériques et en accélérant l’exécution des essais cliniques. Glooko est déployé dans le monde entier, dans plus de 30 pays et plus de 8 000 sites cliniques.

Glooko.com LinkedIn.com Twitter Instagram Facebook

###

Contact pour les médias
Tanya Rodante
Directrice de la communication – Global
[email protected]

Las mejoras ofrecen una experiencia más fluida y allanan el camino para una atención sanitaria con «Precision Engagement».

Palo Alto, CA, EE. UU., 9 de mayo de 2023: Glooko, Inc. ha anunciado hoy el rediseño de su galardonada aplicación móvil para su plataforma de atención conectada, que proporcionará una experiencia más optimizada a sus usuarios de dispositivos móviles. El diseño elegante y moderno facilita aún más la navegación por todas las potentes funciones de la aplicación móvil de Glooko para una mejor gestión de la diabetes. Cuando se conecta con los profesionales sanitarios del usuario, la última versión de la aplicación también incluye mejoras que permitirán la personalización de su atención a través de un próximo avance llamado «Precision Engagement».

«Como líder mundial en atención conectada, Glooko ha estado a la vanguardia en el desarrollo de nuestra aplicación móvil para mejorar la gestión de la diabetes», explica Ed Marshall, Director de producto de Glooko. «En un contexto como el actual, en el que la atención sanitaria está cada vez más fragmentada, es un privilegio y una gran oportunidad para Glooko reforzar las conexiones entre los pacientes y su equipo de atención médica. Esta es una inversión importante que Glooko está haciendo para seguir mejorando la experiencia del usuario, para que sea más práctica, más personalizada y, en última instancia, para que tenga más impacto».

En el desarrollo de la nueva aplicación, la participación de los usuarios ha sido clave. El rediseño de la aplicación se basó en los comentarios de los usuarios de Glooko, que verán mejoras visuales y un nuevo diseño unificado como parte de una evolución general de la plataforma de salud digital.

Entre las mejoras se incluyen las siguientes:

• Interfaz de usuario y visualización de datos: El nuevo diseño de la aplicación móvil facilita a los usuarios organizar sus datos en un solo lugar y compartirlos con sus profesionales sanitarios; es decir, las tendencias de glucosa, la dosis de insulina, la alimentación, el ejercicio, el peso y la presión arterial. Los usuarios verán el nombre de su equipo de atención médica o clínica en la parte superior de la pantalla y podrán hacer clic para compartir informes con su profesional sanitario y ver todos los equipos de atención activos en un solo lugar.

• Pantalla de inicio: La nueva navegación ayuda a los usuarios a acceder de forma eficiente a las funciones más populares, como el registro de alimentos y el intercambio de datos con los equipos de atención, disponibles con un solo gesto y con los datos más actuales sobre su salud. La pantalla de inicio de un solo gesto también incluye la configuración del perfil, el nombre del equipo de atención, los objetivos, el historial, los dispositivos conectados, un botón para añadir un nuevo evento y tablas y gráficos con dos semanas de datos.

• Proceso de incorporación: Para los usuarios nuevos en Glooko, la experiencia de incorporación es ahora más fácil; el proceso de incorporación reimaginado está dirigido y orienta a los nuevos usuarios de una manera sencilla, poco a poco, que les permite hacerlo a su propio ritmo. A los nuevos usuarios se les orienta más fácilmente a la hora de seleccionar un dispositivo de glucosa, seleccionar un dispositivo de insulina y completar su perfil.

• Precision Engagement: El nuevo diseño se construyó con la capacidad específica de albergar la próxima funcionalidad de Glooko de «Precision Engagement». Las herramientas de Precision Engagement aprovechan los datos ambientales, conductuales y fisiológicos de los dispositivos médicos, los dispositivos portátiles, los dispositivos de consumo y los teléfonos inteligentes para comprender mejor las preferencias únicas de un usuario, sus hábitos y su entorno. Con estos conocimientos únicos, Glooko detecta los momentos adecuados y pretende ofrecer recomendaciones personalizadas para influir en el comportamiento. Glooko ofrecerá más información sobre Precision Engagement próximamente.

Las actualizaciones coinciden con otros hitos importantes para Glooko:

• La aplicación móvil está disponible en más de 30 países y más de 20 idiomas, y sigue creciendo.

• Glooko es ahora compatible con más de 200 dispositivos biométricos y de diabetes en todo el mundo, la mayor compatibilidad de cualquier plataforma de atención conectada.

• Más de 8000 clínicas de todo el mundo atienden a pacientes que usan Glooko.

• Glooko es la única plataforma de atención conectada compatible con las principales plumas inteligentes de insulina y los fabricantes farmacéuticos.

Acerca de Glooko
Glooko mejora los resultados de salud de las personas con enfermedades crónicas a través de su plataforma de atención personalizada, inteligente y conectada. Nuestras tecnologías, de eficacia probada, mejoran la vida de las personas al revolucionar la conexión entre pacientes y profesionales sanitarios, impulsando el compromiso y la adherencia de los pacientes a través de los tratamientos digitales y acelerando la velocidad de los ensayos clínicos. Glooko está presente en más de 30 países y en más de 8000 clínicas.

Glooko.com LinkedIn.com Twitter Instagram Facebook

###

Media Contact
Tanya Rodante
Directora de Comunicaciones globales
[email protected]

Enhancements Offer a More Seamless Experience and Pave the Way for ‘Precision Engagement’ Healthcare

Palo Alto, CA, USA – May 9, 2023 – Glooko, Inc., today announced the redesign of their award-winning mobile app for its connected care platform, that will provide a more streamlined experience for its mobile users. The sleek, modern design makes it even easier to navigate all of Glooko’s robust mobile app features for better diabetes management. When connected to the user’s healthcare providers (HCPs), the latest version of the app also includes enhancements that will allow for personalization of their care via an upcoming advancement called ‘Precision Engagement.’

“As a global leader in Connected Care, Glooko has been at the forefront of leveraging our mobile app for improved diabetes management,” said Ed Marshall, Chief Product Officer at Glooko. “With today’s increasingly fragmented healthcare delivery, it’s a privilege and a huge opportunity for Glooko to strengthen the connections between patients and their care team. This is an important investment Glooko is making to continue to upgrade the user experience, making it more convenient, more personalized, and ultimately more impactful.”

While developing the new app experience, user engagement was key. The app redesign was informed by feedback from Glooko users who will see visual improvements and a new unified design as part of an overall evolution of the digital health platform.

The enhancements include the following:

• User Interface and Data Visualization -> The new mobile app design makes it easier for users to organize their data in one place and share with their HCPs; i.e. glucose trends, insulin doses, food, exercise, weight and blood pressure. Users will see their health care team or clinic name at the top of the screen and can click to share reports with their HCP and see all active care teams in one place.

• Home Screen -> New navigation helps users access popular features efficiently like food logging and sharing data with care teams, available with one scroll and featuring the most current data on their health. The home screen one-scroll feature also includes: profile settings, care team name, goals, history, connected devices, button to add new event, charts and graphs with two weeks of data.

• Onboarding Process -> For users new to Glooko, the onboarding experience is now easier; the reimagined onboarding process is guided and walks new users through it in a simple, “bite-sized” way that allows them to do it at their own pace. New users are guided to more easily: select a glucose device, select an insulin device, complete their profile.

• Precision Engagement -> The new design was built with the specific ability to house Glooko’s upcoming functionality of ‘Precision Engagement.’ Precision Engagement tools leverage environmental, behavioral, and physiologic data from medical devices, wearables, consumer devices, and smartphones to better understand an individual’s unique preferences, habits, and environment. With these unique insights, Glooko detects the right moments and aims to deliver personalized recommendations to help influence behavior. More to come from Glooko on Precision Engagement in the near future.

The updates coincide with other major milestones for Glooko:

• The mobile app is available globally in 30+ countries and 20+ languages and growing.

• Glooko is now compatible with over 200 diabetes and biometric devices worldwide, the largest compatibility of any connected care platform.

• Over 8,000 clinics globally provide care to patients using Glooko.

• Glooko is the only connected care platform that is compatible with all the major smart insulin pens and pharmaceutical manufacturers.

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations.

Glooko.com LinkedIn.com Twitter Instagram Facebook

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

La colaboración brinda atención personalizada para la diabetes

Palo Alto, CA (EE. UU.) – 11 de abril de 2023: Glooko, Inc. ha anunciado hoy una nueva colaboración global con Hedia. Con esta colaboración, integra su tecnología en la plataforma para el control de la diabetes de Glooko para profesionales de la salud y personas con diabetes. Gracias a esta colaboración, se creará una solución interoperativa que aúna atención conectada, supervisión remota de pacientes y tecnologías terapéuticas digitales para mejorar el acceso de las personas con diabetes tipo 1 y tipo 2 que requieren consejos de administración de la insulina en bolo.

Con la plataforma de Glooko, los pacientes actualmente pueden compartir sus datos de diabetes con sus profesionales sanitarios, incluidas las lecturas de glucemia, la dosis de insulina, los alimentos y los carbohidratos, la actividad física, la tensión arterial y el peso. Con la integración de Hedia Diabetes Assistant, las personas con diabetes podrán recibir consejos sobre la dosificación de insulina en bolo, lo que proporcionará atención personalizada y acabará con la necesidad de calcular manualmente las dosis de insulina necesarias. Además, si se utiliza con plumas de insulina conectadas*, la solución integrada ofrece un gran nivel de visibilidad a los profesionales sanitarios que tratan a pacientes con múltiples inyecciones diarias (MDI). Esta integración mejora las capacidades de supervisión remota de pacientes de Glooko y es compatible con consultas virtuales para pacientes con MDI.

“Nos complace enormemente nuestra colaboración con Hedia, que nos permite crear esta innovación impulsada por algoritmos para la atención médica personalizada de pacientes diabéticos y sus equipos de atención médica”, comenta Russ Johannesson, director ejecutivo de Glooko. “Los fiables datos clínicos que respaldan la eficacia de Hedia demuestran que esta podría ser una alternativa viable para los pacientes que no pueden acceder a las bombas de insulina. Con esta asociación se demuestra cómo la interoperabilidad ofrece a las personas con diabetes las herramientas óptimas para facilitar el control de su enfermedad y mejorar su salud, como la estabilidad de los niveles de glucemia”.

Peter Lucas, director ejecutivo de Hedia, afirma: “Estamos encantados de que Glooko, una empresa con una amplia red clínica, sea nuestro socio en salud digital. Además de nuestra gran evidencia clínica, una de las cuestiones clave que tenemos en cuenta al crear nuestra tecnología es el cumplimiento de las normativas y la ciberseguridad. Glooko ha demostrado su fortaleza en estas áreas con varias certificaciones de terceros y eso es un factor clave de nuestra asociación. La designación de dispositivos médicos de clase IIb de Hedia garantiza que se proporcionen las mejores soluciones a los pacientes y a sus equipos de atención.”

Se espera que el lanzamiento inicial europeo de la integración tenga lugar en el cuarto trimestre de 2023 y el primer trimestre de 2024.

*La función de pluma conectada solo está disponible en la UE.

Acerca de Glooko
Glooko mejora los resultados de salud de las personas con enfermedades crónicas a través de su plataforma de atención personalizada, inteligente y conectada. Nuestras tecnologías, de eficacia probada, mejoran la vida de las personas al revolucionar la conexión entre pacientes y proveedores, impulsando el compromiso y la adherencia de los pacientes a través de los tratamientos digitales y acelerando la velocidad de los ensayos clínicos. Glooko trabaja en más de 30 países y en más de 8000 clínicas.

Glooko.com LinkedIn.com Twitter Instagram Facebook

Acerca de Hedia
Hedia es una empresa líder en productos terapéuticos digitales para la diabetes, comprometida con ayudar a las personas con diabetes dependiente de la insulina a controlar su enfermedad. Facilitar la vida a las personas con diabetes ha sido el motor desde la creación de Hedia Diabetes Assistant y la solución está disponible hoy en 11 países. Según los hábitos de la persona con diabetes y los datos personalizados, nuestra aplicación para la diabetes genera recomendaciones de insulina a partir de muchos aspectos del control de la diabetes, como el registro de las lecturas de glucemia, el seguimiento de la insulina activa, la medición de carbohidratos, el cálculo de la dosis de insulina, el seguimiento de la actividad y el registro de los niveles de cetonas en sangre.

Hedia.com LinkedIn

###

Contacto de prensa
Tanya Rodante
Director of Global Communication
[email protected]